The blood brain barrier (BBB) is a highly regulated and efficient barrier that protects the brain and critical parts of the central nervous system (CNS). Unfortunately, the transport of drugs to the brain is hampered by this almost impenetrable, highly selective barrier. This problem is exacerbated for biotherapeutics, which are often orders of magnitude larger than small molecule drugs and more sensitive to environmental effects. Treatment of over 1000 different CNS disorders is currently hampered by the inability to traverse the BBB. However, thanks to some very innovative approaches to address this issue, significant progress has been made in recent years, and will be the focus of this session.

3:30 PM – 3:55 PM Danika Stanimirovic, Ph.D. Institute for Biological Sciences, National Research Council, University of Ottawa Talk Title: “A Gateway to the Brain: Blood-Brain Barrier Shuttles and Trojan Antibodies” 3:55 PM – 4:20 PM Reinhard Gabathuler, Ph.D. Chief Scientist, biOasis 4:20 PM – 4:30 PM Barry Springer, Ph.D – Closing Remarks Vice President Strategy, Technology & External Innovation Janssen BioTherapeutics, Janssen Research & Development, LLC

This program is organized and sponsored by Janssen Biotherapeutics.

Session ID: 14323